Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on by Dana-Farber’s Breast Oncology Center, on X, adding:
“One of the first attempts to crack cell cycle resistance in HR+ breast cancer by adding CDK2 coverage. Many more clinical trials are ongoing with selective CDK2 inhibitors-recycle cell cycle”
Quoting Dana-Farber’s Breast Oncology Center‘s post:
“Check out this First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.”
Title: First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Authors: Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, Antonio Giordano, Igor Bondarenko, Toshinari Yamashita, Li Zhou, Allison Moreau, Heather Neumann, Jessica Tougias, Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri
More posts featuring Antonio Giordano on OncoDaily.